147 related articles for article (PubMed ID: 29100435)
21. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3.
Jiang R; Tan Z; Deng L; Chen Y; Xia Y; Gao Y; Wang X; Sun B
Hepatology; 2011 Sep; 54(3):900-9. PubMed ID: 21674558
[TBL] [Abstract][Full Text] [Related]
22. Quercetin shows anti-tumor effect in hepatocellular carcinoma LM3 cells by abrogating JAK2/STAT3 signaling pathway.
Wu L; Li J; Liu T; Li S; Feng J; Yu Q; Zhang J; Chen J; Zhou Y; Ji J; Chen K; Mao Y; Wang F; Dai W; Fan X; Wu J; Guo C
Cancer Med; 2019 Aug; 8(10):4806-4820. PubMed ID: 31273958
[TBL] [Abstract][Full Text] [Related]
23. IL-9 promotes proliferation and metastasis of hepatocellular cancer cells by activating JAK2/STAT3 pathway.
Lei RE; Shi C; Zhang PL; Hu BL; Jiang HX; Qin SY
Int J Clin Exp Pathol; 2017; 10(7):7940-7946. PubMed ID: 31966644
[TBL] [Abstract][Full Text] [Related]
24. The role of the key autophagy kinase ULK1 in hepatocellular carcinoma and its validation as a treatment target.
Xue ST; Li K; Gao Y; Zhao LY; Gao Y; Yi H; Jiang JD; Li ZR
Autophagy; 2020 Oct; 16(10):1823-1837. PubMed ID: 31986961
[TBL] [Abstract][Full Text] [Related]
25. A new xanthatin analogue 1β-hydroxyl-5α-chloro-8-epi-xanthatin induces apoptosis through ROS-mediated ERK/p38 MAPK activation and JAK2/STAT3 inhibition in human hepatocellular carcinoma.
Fang XY; Zhang H; Zhao L; Tan S; Ren QC; Wang L; Shen XF
Biochimie; 2018 Sep; 152():43-52. PubMed ID: 29960031
[TBL] [Abstract][Full Text] [Related]
26. IL-17A promotes the invasion-metastasis cascade via the AKT pathway in hepatocellular carcinoma.
Xu QG; Yu J; Guo XG; Hou GJ; Yuan SX; Yang Y; Yang Y; Liu H; Pan ZY; Yang F; Gu FM; Zhou WP
Mol Oncol; 2018 Jun; 12(6):936-952. PubMed ID: 29689643
[TBL] [Abstract][Full Text] [Related]
27. Anti‑cancer effects of a novel Pan‑RAF inhibitor in a hepatocellular carcinoma cell line.
Wang W; Xu B; Li Q; Jiang D; Yan S
Mol Med Rep; 2018 Apr; 17(4):6185-6193. PubMed ID: 29484394
[TBL] [Abstract][Full Text] [Related]
28. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory microenvironment of fibrotic liver promotes hepatocellular carcinoma growth, metastasis and sorafenib resistance through STAT3 activation.
Jiang Y; Chen P; Hu K; Dai G; Li J; Zheng D; Yuan H; He L; Xie P; Tu M; Peng S; Qu C; Lin W; Chung RT; Hong J
J Cell Mol Med; 2021 Feb; 25(3):1568-1582. PubMed ID: 33410581
[TBL] [Abstract][Full Text] [Related]
30. PHD2 acts as an oncogene through activation of Ras/Raf/MEK/ERK and JAK1/STAT3 pathways in human hepatocellular carcinoma cells.
Guo J; Lan Z
Artif Cells Nanomed Biotechnol; 2020 Dec; 48(1):37-45. PubMed ID: 31852247
[No Abstract] [Full Text] [Related]
31. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
[TBL] [Abstract][Full Text] [Related]
32. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Zhang W; Sun HC; Wang WQ; Zhang QB; Zhuang PY; Xiong YQ; Zhu XD; Xu HX; Kong LQ; Wu WZ; Wang L; Song TQ; Li Q; Tang ZY
Gastroenterology; 2012 Dec; 143(6):1641-1649.e5. PubMed ID: 22922424
[TBL] [Abstract][Full Text] [Related]
33. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma.
Sun BS; Dong QZ; Ye QH; Sun HJ; Jia HL; Zhu XQ; Liu DY; Chen J; Xue Q; Zhou HJ; Ren N; Qin LX
Hepatology; 2008 Dec; 48(6):1834-42. PubMed ID: 18972404
[TBL] [Abstract][Full Text] [Related]
34. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
[TBL] [Abstract][Full Text] [Related]
35. Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Wang L; Jia D; Duan F; Sun Z; Liu X; Zhou L; Sun L; Ren S; Ruan Y; Gu J
Biochem Biophys Res Commun; 2012 Jun; 422(4):687-92. PubMed ID: 22634008
[TBL] [Abstract][Full Text] [Related]
36. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
37. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
38. Decreased IL-6 induces sensitivity of hepatocellular carcinoma cells to sorafenib.
Yang J; Wang J; Luo J
Pathol Res Pract; 2019 Oct; 215(10):152565. PubMed ID: 31387809
[TBL] [Abstract][Full Text] [Related]
39. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
[TBL] [Abstract][Full Text] [Related]
40. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Chen KF; Chen HL; Shiau CW; Liu CY; Chu PY; Tai WT; Ichikawa K; Chen PJ; Cheng AL
Br J Pharmacol; 2013 Feb; 168(3):658-72. PubMed ID: 22978563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
